MoonLake Immunotherapeutics MLTX Income Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $202.86M+79.9% | $112.77M+255% | $31.8M-24.7% | $42.25M— | ||
| $244.84M+71.1% | $143.09M+164% | $54.12M-16.8% | $65.06M— | ||
| $244.84M+71.1% | $143.09M+164% | $54.12M-16.8% | $65.06M— | ||
| $611K+117% | $282K+200% | $94K+158% | $36.37K— | ||
| -$227.32M-91.1% | -$118.94M-230% | -$36.01M+34.8% | -$55.22M+40.4% | ||
| -$3.52-86.2% | -$1.89-155% | -$0.74+82.4% | -$4.21— | ||
| $254.35M+1.2% | $251.28M+35.5% | $185.42M+74.1% | $106.5M-4.5% | ||
| 254.4M+1.2% | 251.3M+35.5% | 185.4M+74.1% | 106.5M— | ||
| -$231.73M-99.1% | -$116.38M-237% | -$34.51M+36.8% | -$54.6M— | ||
| —— | $5.17M— | —— | $5.96M-18.8% | ||
| -$561K— | —— | $6.35M— | —— | ||
| $146M+185% | $51.31M-89.3% | $479.7M+358% | $104.84M+46.6% | ||
| —— | —— | —— | —— | ||
| -$196.01M-68.1% | -$116.59M-173% | -$42.78M-0.7% | -$42.5M-6,855% | ||
| $641K— | —— | -$336K— | —— | ||
| -$5.12M-291% | $2.69M— | —— | $390.75K— | ||
| -$4.8M-285% | $2.6M— | —— | $660.65K— | ||
| $22.37M+1.1% | $22.13M+118% | $10.14M+1,613% | $591.73K— | ||
| -$242.22M-70.9% | -$141.71M-164% | -$53.75M-4.0% | -$51.67M— | ||
| -$244.84M-71.1% | -$143.09M-164% | -$54.12M-4.4% | -$51.83M-1,034% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Is MoonLake Immunotherapeutics profitable?
- MoonLake Immunotherapeutics is not currently profitable: it reported a net loss of $257.1M over the trailing twelve months.
- What is MoonLake Immunotherapeutics's earnings per share?
- MoonLake Immunotherapeutics's diluted EPS over the trailing twelve months is $-3.87.
- Where does MoonLake Immunotherapeutics's income statement data come from?
- Every line is extracted from MoonLake Immunotherapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.